TriSalus Life Sciences Q1 2024 GAAP EPS $(0.60) Beats $(0.65) Estimate, Sales $6.457M Beat $6.178M Estimate
$TLSI
Medical Specialities
Health Care
TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.65) by 7.69 percent. This is a 5.26 percent decrease over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $6.457 million which beat the analyst consensus estimate of $6.178 million by 4.51 percent. This is a 116.39 percent increase over sales of $2.984 million the same period last year.